枯草杆菌二联活菌对结肠癌患者小肠细菌过度生长的影响(1)
[摘要] 目的 探讨结肠癌患者小肠细菌过度生长(SIBO)的检测及枯草杆菌二联活菌对其的影响。 方法 选取2015年1月～2016年5月于我院接受结肠癌手术治疗的患者86例为观察组，同时选取同期来院体检的健康者62例为对照组。所有研究对象均进行葡萄糖氢呼气试验，检测SIBO情况。将表现为SIBO阳性的结肠癌患者随机分为A、B两组。A组患者仅进行利福昔明治療，B组在A组基础上服用枯草杆菌二联活菌颗粒。观察两组研究对象SIBO阳性率、治疗前后A、B两组胃肠道症状积分及治疗后A、B两组SIBO转阴率情况。 结果 观察组SIBO阳性率为60.47%(52例)，明显高于健康体检者组成的对照组的SIBO阳性率9.68%(6例)(P<0.05)。治疗前，A、B两组的胃肠道症状积分得分相比，差异无统计学意义(P>0.05)。A、B两组治疗后的胃肠道症状积分均低于治疗前(P<0.05)。治疗后，A组的胃肠道症状积分为(9.11±0.83)分，明显高于B组的(8.75±0.57)分(P<0.05)。治疗后，A组的SIBO转阴率为34.62%，明显低于B组的88.46%(P<0.05)。 结论 结肠癌术后患者相对于健康人发生SIBO可能性更高。枯草杆菌二联活菌联合利福昔明治疗结肠癌术后SIBO效果较好，能够明显改善患者的胃肠道状况，提高SIBO的转阴率。
[关键词] 结肠癌；小肠细菌过度生长；枯草杆菌二联活菌
[中图分类号] R735.3 [文献标识码] A [文章编号] 1673-9701(2017)36-0026-04
[Abstract] Objective To investigate the detection of small intestinal bacterial overgrowth(SIBO) in colon cancer patients and the effect of viable combined bacillus subtilis on it. Methods From January 2015 to May 2016， 86 patients who were given the surgery of colon cancer were selected as the observation group. At the same time， 62 healthy subjects who were given physical examination in our hospital were selected as the control group. All subjects were given glucose hydrogen breath test to detect SIBO condition. Patients with colon cancer and with positive SIBO were randomly divided into group A and group B. Patients in group A were treated with rifaximin only， and patients in group B were given viable combined bacillus subtilis on the basis of group A. The positive rates of SIBO in both groups， the scores of gastrointestinal symptoms in groups A and B before and after treatment and the SIBO negative turning rates in groups A and B after treatment were observed. Results The positive rate of SIBO in the observation group was 60.47% (52 cases)， which was significantly higher than that of 9.68% (6 cases) in the healthy subjects in the control group(P<0.05). Before treatment， the gastrointestinal symptom scores were compared between group A and group B， and the difference was not significant(P>0.05). Gastrointestinal symptom scores in group A and group B after the treatment were lower than those before treatment(P<0.05). After treatment， the score of gastrointestinal symptoms in group A was(9.11±0.83) points， significantly higher than that in group B(8.75±0.57)(P<0.05). After treatment， the SIBO negative turning rate in group A was 34.62%， which was significantly lower than that of 88.46% in group B(P<0.05). Conclusion Patients with postoperative colon cancer has a higher possibility of SIBO compared with healthy people. Viable combined bacillus subtilis combined with rifaximin in the treatment of SIBO after the surgery of colon cancer has a better effect， which can significantly improve the patient's gastrointestinal conditions， and improve the SIBO negative turning rate., http://www.100md.com(孙柯科 胡萍萍 许丰 李小平 陆德文)
[关键词] 结肠癌；小肠细菌过度生长；枯草杆菌二联活菌
[中图分类号] R735.3 [文献标识码] A [文章编号] 1673-9701(2017)36-0026-04
[Abstract] Objective To investigate the detection of small intestinal bacterial overgrowth(SIBO) in colon cancer patients and the effect of viable combined bacillus subtilis on it. Methods From January 2015 to May 2016， 86 patients who were given the surgery of colon cancer were selected as the observation group. At the same time， 62 healthy subjects who were given physical examination in our hospital were selected as the control group. All subjects were given glucose hydrogen breath test to detect SIBO condition. Patients with colon cancer and with positive SIBO were randomly divided into group A and group B. Patients in group A were treated with rifaximin only， and patients in group B were given viable combined bacillus subtilis on the basis of group A. The positive rates of SIBO in both groups， the scores of gastrointestinal symptoms in groups A and B before and after treatment and the SIBO negative turning rates in groups A and B after treatment were observed. Results The positive rate of SIBO in the observation group was 60.47% (52 cases)， which was significantly higher than that of 9.68% (6 cases) in the healthy subjects in the control group(P<0.05). Before treatment， the gastrointestinal symptom scores were compared between group A and group B， and the difference was not significant(P>0.05). Gastrointestinal symptom scores in group A and group B after the treatment were lower than those before treatment(P<0.05). After treatment， the score of gastrointestinal symptoms in group A was(9.11±0.83) points， significantly higher than that in group B(8.75±0.57)(P<0.05). After treatment， the SIBO negative turning rate in group A was 34.62%， which was significantly lower than that of 88.46% in group B(P<0.05). Conclusion Patients with postoperative colon cancer has a higher possibility of SIBO compared with healthy people. Viable combined bacillus subtilis combined with rifaximin in the treatment of SIBO after the surgery of colon cancer has a better effect， which can significantly improve the patient's gastrointestinal conditions， and improve the SIBO negative turning rate., http://www.100md.com(孙柯科 胡萍萍 许丰 李小平 陆德文)
参见：首页 > 医疗版 > 疾病专题 > 消化内科 > 肠道疾病 > 类癌及类癌综合征 > 结、直肠癌